On-X Aortic Prosthetic Heart Valve Low Dose Warfarin Post Approval Clinical Registry Study
Prospective Randomized On-X Anticoagulation Clinical Trial Mitral Arm
On-X bi-leaflet mechanical heart valve in the mitral position.
A Trial to Determine if Participants with an On-X Aortic Valve Can Be Safely Maintained On Apixaban
On-X Heart Valve Clinical Milestones
US FDA approves On-X Aortic Valve with Standard sewing ring.
US FDA approves On-X Mitral Valve with Standard and Conform-X sewing rings. CE mark approval for Aortic Valve with Conform-X sewing ring.
US FDA approves IDE trial for lowered anticoagulation for the On-X Prosthetic Heart Valves (PROACT).
Enrollment complete in the PROACT Aortic Valve Replacement high-risk aortic patient group.
US FDA approves On-X Aortic Heart Valves with INR 1.5–2.0 after 3 months standard anticoagulation.
2017 AHA/ACC Guidelines include On-X Aortic Valve INR 1.5-2.0 in patients without risk of TE.2,*
*After 3 months standard therapy.
Enrollment in PROACT Xa Clinical Trial commences to determine if participants with On-X Aortic Valve can take apixaban oral medication instead of warfarin.
Enrollment complete for Mitral Arm of PROACT.
Clinical Trial References
- Otto CM, et al. Circulation. 2021;143: doi: 10.1161/CIR.0000000000000923.
- Granger C. et al. N Engl J Med 2011; 365:981-992 DOI: 10.1056/NEJMoa1107039.
Important Safety Information
Know the Facts
Your choice of aortic or mitral heart valve can affect how long and how well you live.
See what other heart valve patients have to say. Click below to watch videos.
Find a Surgeon
Find an experienced valve replacement surgeon in your area.